---
title: Epigenetic agents plus anti-PD-1 reshapes tumor microenvironment and restores
  antitumor efficacy in Hodgkin lymphoma
date: '2024-08-02'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39093981/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240803181345&v=2.18.0.post9+e462414
source: Blood
description: DNA methyltransferase inhibitor decitabine plus anti-PD-1 (DP) combination
  therapy was effective in relapsed/refractory classic Hodgkin lymphoma (cHL). However,
  a subset of patients experienced primary resistance or relapse/progression after
  DP therapy. In this study, we evaluated the efficacy and safety of a triplet regimen
  consisting of the histone deacetylase inhibitor chidamide, decitabine and anti-PD-1
  camrelizumab (CDP) in 52 patients with relapsed/refractory cHL who had ...
disable_comments: true
---
DNA methyltransferase inhibitor decitabine plus anti-PD-1 (DP) combination therapy was effective in relapsed/refractory classic Hodgkin lymphoma (cHL). However, a subset of patients experienced primary resistance or relapse/progression after DP therapy. In this study, we evaluated the efficacy and safety of a triplet regimen consisting of the histone deacetylase inhibitor chidamide, decitabine and anti-PD-1 camrelizumab (CDP) in 52 patients with relapsed/refractory cHL who had ...